Profile data is unavailable for this security.
About the company
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.
- Revenue in CAD (TTM)0.00
- Net income in CAD-1.94m
- Incorporated2014
- Employees--
- LocationHemostemix Inc707 7th Ave. SW, Suite 1150CALGARY T2P 3H6CanadaCAN
- Phone+1 (905) 580-4170
- Fax+1 (403) 818-7672
- Websitehttps://hemostemix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Appili Therapeutics Inc | 827.41k | -3.82m | 3.05m | 7.00 | -- | -- | -- | 3.68 | -0.0315 | -0.0315 | 0.0068 | -0.1021 | 0.3758 | -- | 0.6463 | 118,201.40 | -173.36 | -128.44 | -- | -251.87 | -- | -- | -461.35 | -2,103.81 | -- | -3.30 | -- | -- | 147.59 | -- | 59.09 | -- | 17.59 | -- |
StageZero Life Sciences Ltd | -100.00bn | -100.00bn | 4.94m | 40.00 | -- | -- | -- | -- | -- | -- | -- | -0.1192 | -- | -- | -- | -- | -- | -135.76 | -- | -- | -- | -2.74 | -- | -246.92 | 0.0204 | -- | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
Quest PharmaTech Inc | 0.00 | 13.58m | 5.10m | 0.00 | 0.3737 | 0.2205 | 0.3754 | -- | 0.0803 | 0.0803 | 0.00 | 0.136 | 0.00 | -- | -- | -- | 53.30 | 7.62 | 55.60 | 8.45 | -- | -- | -- | -- | -- | -- | 0.0417 | 0.00 | -- | -- | 95.35 | -- | -- | -- |
Hemostemix Inc | 0.00 | -1.94m | 5.25m | -- | -- | -- | -- | -- | -0.0214 | -0.0214 | 0.00 | -0.0959 | 0.00 | -- | -- | -- | -705.31 | -599.98 | -- | -- | -- | -- | -- | -- | -- | -1.74 | -- | -- | -- | -- | 52.21 | -- | -- | -- |
Innovotech Inc | 1.23m | -364.50k | 5.30m | 16.00 | -- | 7.22 | -- | 4.31 | -0.0094 | -0.0094 | 0.0315 | 0.0187 | 1.10 | 5.81 | 5.84 | -- | -32.59 | 2.90 | -37.99 | 3.56 | 68.63 | 71.56 | -29.67 | 2.19 | 2.17 | -- | 0.1115 | -- | 5.05 | 7.42 | -15.43 | -- | 35.69 | -- |
Principal Technologies Inc | 618.64k | -1.90m | 5.93m | -- | -- | 9.72 | -- | 9.58 | -0.0766 | -0.0766 | 0.0246 | 0.0165 | 0.5664 | -- | 2.92 | -- | -170.72 | -- | -445.11 | -- | 21.57 | -- | -301.45 | -- | -- | -31.95 | 0.0959 | -- | 25.43 | -- | 23.53 | -- | -- | -- |
Marvel Biosciences Corp | 0.00 | -2.10m | 6.75m | -- | -- | -- | -- | -- | -0.0529 | -0.0529 | 0.00 | -0.0693 | 0.00 | -- | -- | -- | -268.48 | -- | -- | -- | -- | -- | -- | -- | -- | -14.33 | -- | -- | -- | -- | 10.29 | -- | -- | -- |
XORTX Therapeutics Inc | 0.00 | -2.03m | 6.80m | 3.00 | -- | 1.82 | -- | -- | -0.6868 | -0.6868 | 0.00 | 1.28 | 0.00 | -- | -- | -- | -23.54 | -35.42 | -29.36 | -40.37 | -- | -- | -- | -- | -- | -- | 0.03 | -- | -- | -- | 72.04 | -- | 7.91 | -- |